The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research.
The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research.
复制标题
DOI：
10.1097/mog.0b013e32830b111d
复制
发表时间：
2008-09
影响因子：
2.5
通讯作者：
Urrutia R
中科院分区：
文献类型：
--
作者：
Lomberk G;Mathison AJ;Grzenda A;Urrutia R
The excitement of finding a cancer modulator which is either mutated or deleted in vivo (Genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the other hand, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (Epigenetics), for example, is reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics, and its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. Special focus has been given to novel potential therapeutic targets and currently available drugs which are emerging from this exciting new field of pancreatic cancer research.
